Of the many targeted therapies introduced since 2006, sunitinib has carved its way to
become the most commonly used first-line therapy for the treatment of metastatic renal cell …

Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …

Sunitinib is the first‐line drug for renal cell carcinoma (RCC) treatment. However, patients
who received sunitinib treatment will ultimately develop drug resistance after 6–15 months …

Sunitinib is one of the most widely used targeted therapeutics for renal cell carcinoma
(RCC), but acquired resistance against targeted therapies remains a major clinical …

The introduction of agents that inhibit tumor angiogenesis by targeting vascular endothelial
growth factor (VEGF) signaling has made a significant impact on the survival of patients with …

Aim Although targeting angiogenesis with vascular endothelial growth factor receptor
(VEGFR) inhibitors has demonstrated efficacy in the treatment of renal cell carcinoma …

Renal cell carcinoma (RCC) is a highly vascularized tumor type, which is often associated
with inactivated mutations in the von Hippel-Lindau gene that drives proangiogenic …

Resistance in clear cell renal cell carcinoma (ccRCC) against sunitinib is a multifaceted
process encompassing numerous molecular aberrations. This induces clinical …

What's known on the subject? and What does the study add? Although there have been a
few studies investigating the molecular mechanism mediating the acquisition of resistance to …

Introduction: Sunitinib is a multi-target, anti-angiogenic tyrosine kinase inhibitor and a key
molecule in the treatment of metastatic renal cell carcinoma (mRCC). Since it first …